Format
Sort by
Items per page

Send to

Choose Destination

Best matches for López-Andrés N[au]:

Search results

Items: 50

1.

Soluble ST2 promotes oxidative stress and inflammation in cardiac fibroblasts: An in vitro and in vivo study in aortic stenosis.

Matilla L, Ibarrola J, Arrieta V, Garcia-Peña A, Martinez-Martinez E, Sádaba R, Alvarez V, Navarro A, Fernández-Celis A, Gainza A, Santamaría E, Fernández-Irigoyen J, Bayes-Genis A, Rossignol P, López-Andrés N.

Clin Sci (Lond). 2019 Jul 8. pii: CS20190475. doi: 10.1042/CS20190475. [Epub ahead of print]

PMID:
31285364
2.

Myocardial Injury After Ischemia/Reperfusion Is Attenuated By Pharmacological Galectin-3 Inhibition.

Ibarrola J, Matilla L, Martínez-Martínez E, Gueret A, Fernández-Celis A, Henry JP, Nicol L, Jaisser F, Mulder P, Ouvrard-Pascaud A, López-Andrés N.

Sci Rep. 2019 Jul 3;9(1):9607. doi: 10.1038/s41598-019-46119-6.

3.

Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology.

de Boer RA, De Keulenaer G, Bauersachs J, Brutsaert D, Cleland JG, Diez J, Du XJ, Ford P, Heinzel FR, Lipson KE, McDonagh T, Lopez-Andres N, Lunde IG, Lyon AR, Pollesello P, Prasad SK, Tocchetti CG, Mayr M, Sluijter JPG, Thum T, Tschöpe C, Zannad F, Zimmermann WH, Ruschitzka F, Filippatos G, Lindsey ML, Maack C, Heymans S.

Eur J Heart Fail. 2019 Mar;21(3):272-285. doi: 10.1002/ejhf.1406. Epub 2019 Feb 4.

4.

CT-1 (Cardiotrophin-1)-Gal-3 (Galectin-3) Axis in Cardiac Fibrosis and Inflammation.

Martínez-Martínez E, Brugnolaro C, Ibarrola J, Ravassa S, Buonafine M, López B, Fernández-Celis A, Querejeta R, Santamaria E, Fernández-Irigoyen J, Rábago G, Moreno MU, Jaisser F, Díez J, González A, López-Andrés N.

Hypertension. 2019 Mar;73(3):602-611. doi: 10.1161/HYPERTENSIONAHA.118.11874.

PMID:
30612490
5.

Therapeutic Delivery of miR-148a Suppresses Ventricular Dilation in Heart Failure.

Raso A, Dirkx E, Philippen LE, Fernandez-Celis A, De Majo F, Sampaio-Pinto V, Sansonetti M, Juni R, El Azzouzi H, Calore M, Bitsch N, Olieslagers S, Oerlemans MIFJ, Huibers MM, de Weger RA, Reckman YJ, Pinto YM, Zentilin L, Zacchigna S, Giacca M, da Costa Martins PA, López-Andrés N, De Windt LJ.

Mol Ther. 2019 Mar 6;27(3):584-599. doi: 10.1016/j.ymthe.2018.11.011. Epub 2018 Nov 17.

6.

A Global Assessment of Circulating Prolysyl Oxidase in Nonischemic Patients With Garden-variety Heart Failure With Preserved Ejection Fraction.

Muñoz Calvo B, Villa Martínez A, López Orgil S, López Andrés N, Román García F, Víctor Palomares V, de la Calle de la Villa E, Nadador Patiño V, Arribas-Gómez I.

Rev Esp Cardiol (Engl Ed). 2019 May;72(5):407-415. doi: 10.1016/j.rec.2018.04.006. Epub 2018 May 26. English, Spanish.

PMID:
29807761
7.

Aldosterone Impairs Mitochondrial Function in Human Cardiac Fibroblasts via A-Kinase Anchor Protein 12.

Ibarrola J, Sadaba R, Martinez-Martinez E, Garcia-Peña A, Arrieta V, Alvarez V, Fernández-Celis A, Gainza A, Cachofeiro V, Santamaria E, Fernandez-Irigoyen J, Jaisser F, Lopez-Andres N.

Sci Rep. 2018 May 1;8(1):6801. doi: 10.1038/s41598-018-25068-6.

8.

Galectin-3 down-regulates antioxidant peroxiredoxin-4 in human cardiac fibroblasts: a new pathway to induce cardiac damage.

Ibarrola J, Arrieta V, Sádaba R, Martinez-Martinez E, Garcia-Peña A, Alvarez V, Fernández-Celis A, Gainza A, Santamaría E, Fernández-Irigoyen J, Cachofeiro V, Zalba G, Fay R, Rossignol P, López-Andrés N.

Clin Sci (Lond). 2018 Jul 18;132(13):1471-1485. doi: 10.1042/CS20171389. Print 2018 Jul 18.

PMID:
29674526
9.

A role for fumarate hydratase in mediating oxidative effects of galectin-3 in human cardiac fibroblasts.

Ibarrola J, Sádaba R, Garcia-Peña A, Arrieta V, Martinez-Martinez E, Alvarez V, Fernández-Celis A, Gainza A, Santamaría E, Fernández-Irigoyen J, Cachofeiro V, Fay R, Rossignol P, López-Andrés N.

Int J Cardiol. 2018 May 1;258:217-223. doi: 10.1016/j.ijcard.2017.12.103.

PMID:
29544935
10.

Specific Activation of the Alternative Cardiac Promoter of Cacna1c by the Mineralocorticoid Receptor.

Mesquita TR, Auguste G, Falcón D, Ruiz-Hurtado G, Salazar-Enciso R, Sabourin J, Lefebvre F, Viengchareun S, Kobeissy H, Lechène P, Nicolas V, Fernandez-Celis A, Gómez S, Lauton Santos S, Morel E, Rueda A, López-Andrés N, Gómez AM, Lombès M, Benitah JP.

Circ Res. 2018 Mar 30;122(7):e49-e61. doi: 10.1161/CIRCRESAHA.117.312451. Epub 2018 Feb 21.

PMID:
29467196
11.

Inhibition of galectin-3 ameliorates the consequences of cardiac lipotoxicity in a rat model of diet-induced obesity.

Marín-Royo G, Gallardo I, Martínez-Martínez E, Gutiérrez B, Jurado-López R, López-Andrés N, Gutiérrez-Tenorio J, Rial E, Bartolomé MAV, Nieto ML, Cachofeiro V.

Dis Model Mech. 2018 Feb 5;11(2). pii: dmm032086. doi: 10.1242/dmm.032086.

12.

Neutrophil Gelatinase-Associated Lipocalin from immune cells is mandatory for aldosterone-induced cardiac remodeling and inflammation.

Buonafine M, Martínez-Martínez E, Amador C, Gravez B, Ibarrola J, Fernández-Celis A, El Moghrabi S, Rossignol P, López-Andrés N, Jaisser F.

J Mol Cell Cardiol. 2018 Feb;115:32-38. doi: 10.1016/j.yjmcc.2017.12.011. Epub 2017 Dec 28.

PMID:
29289651
13.

The role of oxidative stress in the crosstalk between leptin and mineralocorticoid receptor in the cardiac fibrosis associated with obesity.

Gutiérrez-Tenorio J, Marín-Royo G, Martínez-Martínez E, Martín R, Miana M, López-Andrés N, Jurado-López R, Gallardo I, Luaces M, San Román JA, González-Amor M, Salaices M, Nieto ML, Cachofeiro V.

Sci Rep. 2017 Dec 1;7(1):16802. doi: 10.1038/s41598-017-17103-9.

14.

Aldosterone Target NGAL (Neutrophil Gelatinase-Associated Lipocalin) Is Involved in Cardiac Remodeling After Myocardial Infarction Through NFκB Pathway.

Martínez-Martínez E, Buonafine M, Boukhalfa I, Ibarrola J, Fernández-Celis A, Kolkhof P, Rossignol P, Girerd N, Mulder P, López-Andrés N, Ouvrard-Pascaud A, Jaisser F.

Hypertension. 2017 Dec;70(6):1148-1156. doi: 10.1161/HYPERTENSIONAHA.117.09791. Epub 2017 Oct 23.

PMID:
29061727
15.

Increased galectin-3 levels are associated with abdominal aortic aneurysm progression and inhibition of galectin-3 decreases elastase-induced AAA development.

Fernandez-García CE, Tarin C, Roldan-Montero R, Martinez-Lopez D, Torres-Fonseca M, Lindhot JS, Vega de Ceniga M, Egido J, Lopez-Andres N, Blanco-Colio LM, Martín-Ventura JL.

Clin Sci (Lond). 2017 Nov 6;131(22):2707-2719. doi: 10.1042/CS20171142. Print 2017 Nov 15.

PMID:
28982723
16.

Differential Proteomics Identifies Reticulocalbin-3 as a Novel Negative Mediator of Collagen Production in Human Cardiac Fibroblasts.

Martínez-Martínez E, Ibarrola J, Fernández-Celis A, Santamaria E, Fernández-Irigoyen J, Rossignol P, Jaisser F, López-Andrés N.

Sci Rep. 2017 Sep 22;7(1):12192. doi: 10.1038/s41598-017-12305-7.

17.

Galectin-3 pharmacological inhibition attenuates early renal damage in spontaneously hypertensive rats.

Martínez-Martínez E, Ibarrola J, Fernández-Celis A, Calvier L, Leroy C, Cachofeiro V, Rossignol P, López-Andrés N.

J Hypertens. 2018 Feb;36(2):368-376. doi: 10.1097/HJH.0000000000001545.

PMID:
28858976
18.

Beneficial Effects of Galectin-3 Blockade in Vascular and Aortic Valve Alterations in an Experimental Pressure Overload Model.

Ibarrola J, Martínez-Martínez E, Sádaba JR, Arrieta V, García-Peña A, Álvarez V, Fernández-Celis A, Gainza A, Rossignol P, Cachofeiro Ramos V, López-Andrés N.

Int J Mol Sci. 2017 Jul 31;18(8). pii: E1664. doi: 10.3390/ijms18081664.

19.

Differential proteomics reveals S100-A11 as a key factor in aldosterone-induced collagen expression in human cardiac fibroblasts.

Martínez-Martínez E, Ibarrola J, Lachén-Montes M, Fernández-Celis A, Jaisser F, Santamaría E, Fernández-Irigoyen J, López-Andrés N.

J Proteomics. 2017 Aug 23;166:93-100. doi: 10.1016/j.jprot.2017.07.011. Epub 2017 Jul 22.

PMID:
28739510
20.

A role for galectin-3 in the development of early molecular alterations in short-term aortic stenosis.

Arrieta V, Martinez-Martinez E, Ibarrola J, Alvarez V, Sádaba R, Garcia-Peña A, Fernández-Celis A, Cachofeiro V, Rossignol P, López-Andrés N.

Clin Sci (Lond). 2017 May 1;131(10):935-949. doi: 10.1042/CS20170145. Epub 2017 Mar 30.

PMID:
28360193
21.

Galectin-3 Blockade Reduces Renal Fibrosis in Two Normotensive Experimental Models of Renal Damage.

Martinez-Martinez E, Ibarrola J, Calvier L, Fernandez-Celis A, Leroy C, Cachofeiro V, Rossignol P, Lopez-Andres N.

PLoS One. 2016 Nov 9;11(11):e0166272. doi: 10.1371/journal.pone.0166272. eCollection 2016.

22.

Role for Galectin-3 in Calcific Aortic Valve Stenosis.

Sádaba JR, Martínez-Martínez E, Arrieta V, Álvarez V, Fernández-Celis A, Ibarrola J, Melero A, Rossignol P, Cachofeiro V, López-Andrés N.

J Am Heart Assoc. 2016 Nov 4;5(11). pii: e004360.

23.

Soluble ST2 Levels and Left Ventricular Structure and Function in Patients With Metabolic Syndrome.

Celic V, Majstorovic A, Pencic-Popovic B, Sljivic A, Lopez-Andres N, Roy I, Escribano E, Beunza M, Melero A, Floridi F, Magrini L, Marino R, Salerno G, Cardelli P, Di Somma S.

Ann Lab Med. 2016 Nov;36(6):542-9. doi: 10.3343/alm.2016.36.6.542.

24.

Galectin-3, Cardiac Function, and Fibrosis.

Meijers WC, López-Andrés N, de Boer RA.

Am J Pathol. 2016 Aug;186(8):2232-2234. doi: 10.1016/j.ajpath.2016.05.002. Epub 2016 Jul 20.

PMID:
27461364
25.

Galectin-3 inhibition prevents adipose tissue remodelling in obesity.

Martínez-Martínez E, Calvier L, Rossignol P, Rousseau E, Fernández-Celis A, Jurado-López R, Laville M, Cachofeiro V, López-Andrés N.

Int J Obes (Lond). 2016 Jun;40(6):1034-8. doi: 10.1038/ijo.2016.19. Epub 2016 Feb 8.

PMID:
26853916
26.

The lysyl oxidase inhibitor (β-aminopropionitrile) reduces leptin profibrotic effects and ameliorates cardiovascular remodeling in diet-induced obesity in rats.

Martínez-Martínez E, Rodríguez C, Galán M, Miana M, Jurado-López R, Bartolomé MV, Luaces M, Islas F, Martínez-González J, López-Andrés N, Cachofeiro V.

J Mol Cell Cardiol. 2016 Mar;92:96-104. doi: 10.1016/j.yjmcc.2016.01.012. Epub 2016 Jan 15.

PMID:
26780438
27.

Galectin-3 Participates in Cardiovascular Remodeling Associated With Obesity.

Martínez-Martínez E, López-Ándres N, Jurado-López R, Rousseau E, Bartolomé MV, Fernández-Celis A, Rossignol P, Islas F, Antequera A, Prieto S, Luaces M, Cachofeiro V.

Hypertension. 2015 Nov;66(5):961-9. doi: 10.1161/HYPERTENSIONAHA.115.06032. Epub 2015 Sep 8.

PMID:
26351031
28.

Galectin-3 blockade inhibits cardiac inflammation and fibrosis in experimental hyperaldosteronism and hypertension.

Martínez-Martínez E, Calvier L, Fernández-Celis A, Rousseau E, Jurado-López R, Rossoni LV, Jaisser F, Zannad F, Rossignol P, Cachofeiro V, López-Andrés N.

Hypertension. 2015 Oct;66(4):767-75. doi: 10.1161/HYPERTENSIONAHA.115.05876. Epub 2015 Aug 3.

PMID:
26238446
29.

Searching for new mechanisms of myocardial fibrosis with diagnostic and/or therapeutic potential.

Heymans S, González A, Pizard A, Papageorgiou AP, López-Andrés N, Jaisser F, Thum T, Zannad F, Díez J.

Eur J Heart Fail. 2015 Aug;17(8):764-71. doi: 10.1002/ejhf.312. Epub 2015 Jun 30. Review. Erratum in: Eur J Heart Fail. 2015 Sep;17(9):985.

30.

Neutrophil Gelatinase-Associated Lipocalin, a Novel Mineralocorticoid Biotarget, Mediates Vascular Profibrotic Effects of Mineralocorticoids.

Tarjus A, Martínez-Martínez E, Amador C, Latouche C, El Moghrabi S, Berger T, Mak TW, Fay R, Farman N, Rossignol P, Zannad F, López-Andrés N, Jaisser F.

Hypertension. 2015 Jul;66(1):158-66. doi: 10.1161/HYPERTENSIONAHA.115.05431. Epub 2015 May 18.

PMID:
25987661
31.

Interleukin-33/ST2 system attenuates aldosterone-induced adipogenesis and inflammation.

Martínez-Martínez E, Cachofeiro V, Rousseau E, Álvarez V, Calvier L, Fernández-Celis A, Leroy C, Miana M, Jurado-López R, Briones AM, Jaisser F, Zannad F, Rossignol P, López-Andrés N.

Mol Cell Endocrinol. 2015 Aug 15;411:20-7. doi: 10.1016/j.mce.2015.04.007. Epub 2015 Apr 17.

PMID:
25896545
32.

Pediatric Ferroportin Disease.

Galicia-Poblet G, Cid-París E, López-Andrés N, Losada-Pajares A, Jurado-López JC, Moreno-Carralero MI, Morán-Jiménez MJ.

J Pediatr Gastroenterol Nutr. 2016 Dec;63(6):e205-e207. No abstract available.

33.

Pharmacological inhibition of galectin-3 protects against hypertensive nephropathy.

Frenay AR, Yu L, van der Velde AR, Vreeswijk-Baudoin I, López-Andrés N, van Goor H, Silljé HH, Ruifrok WP, de Boer RA.

Am J Physiol Renal Physiol. 2015 Mar 1;308(5):F500-9. doi: 10.1152/ajprenal.00461.2014. Epub 2014 Dec 10.

34.

The impact of galectin-3 inhibition on aldosterone-induced cardiac and renal injuries.

Calvier L, Martinez-Martinez E, Miana M, Cachofeiro V, Rousseau E, Sádaba JR, Zannad F, Rossignol P, López-Andrés N.

JACC Heart Fail. 2015 Jan;3(1):59-67. doi: 10.1016/j.jchf.2014.08.002. Epub 2014 Nov 11.

35.

Leptin induces cardiac fibrosis through galectin-3, mTOR and oxidative stress: potential role in obesity.

Martínez-Martínez E, Jurado-López R, Valero-Muñoz M, Bartolomé MV, Ballesteros S, Luaces M, Briones AM, López-Andrés N, Miana M, Cachofeiro V.

J Hypertens. 2014 May;32(5):1104-14; discussion 1114. doi: 10.1097/HJH.0000000000000149.

PMID:
24695395
36.

The potential role of leptin in the vascular remodeling associated with obesity.

Martínez-Martínez E, Miana M, Jurado-López R, Bartolomé MV, Souza Neto FV, Salaices M, López-Andrés N, Cachofeiro V.

Int J Obes (Lond). 2014 Dec;38(12):1565-72. doi: 10.1038/ijo.2014.37. Epub 2014 Mar 3.

PMID:
24583853
37.

A role for soluble ST2 in vascular remodeling associated with obesity in rats.

Martínez-Martínez E, Miana M, Jurado-López R, Rousseau E, Rossignol P, Zannad F, Cachofeiro V, López-Andrés N.

PLoS One. 2013 Nov 12;8(11):e79176. doi: 10.1371/journal.pone.0079176. eCollection 2013.

38.

Absence of cardiotrophin 1 is associated with decreased age-dependent arterial stiffness and increased longevity in mice.

López-Andrés N, Calvier L, Labat C, Fay R, Díez J, Benetos A, Zannad F, Lacolley P, Rossignol P.

Hypertension. 2013 Jan;61(1):120-9. doi: 10.1161/HYPERTENSIONAHA.112.201699. Epub 2012 Nov 19.

PMID:
23172930
39.

Galectin-3 mediates aldosterone-induced vascular fibrosis.

Calvier L, Miana M, Reboul P, Cachofeiro V, Martinez-Martinez E, de Boer RA, Poirier F, Lacolley P, Zannad F, Rossignol P, López-Andrés N.

Arterioscler Thromb Vasc Biol. 2013 Jan;33(1):67-75. doi: 10.1161/ATVBAHA.112.300569. Epub 2012 Nov 1.

PMID:
23117656
40.

[A case of Alice-in-Wonderland syndrome probably associated with the use of montelukast].

Bernal Vañó E, López Andrés N.

An Pediatr (Barc). 2013 Feb;78(2):127-8. doi: 10.1016/j.anpedi.2012.06.010. Epub 2012 Jul 31. Spanish. No abstract available.

41.

Increased microparticle production and impaired microvascular endothelial function in aldosterone-salt-treated rats: protective effects of polyphenols.

López Andrés N, Tesse A, Regnault V, Louis H, Cattan V, Thornton SN, Labat C, Kakou A, Tual-Chalot S, Faure S, Challande P, Osborne-Pellegrin M, Martínez MC, Lacolley P, Andriantsitohaina R.

PLoS One. 2012;7(7):e39235. doi: 10.1371/journal.pone.0039235. Epub 2012 Jul 10.

42.

Cardiotrophin 1 is involved in cardiac, vascular, and renal fibrosis and dysfunction.

López-Andrés N, Rousseau A, Akhtar R, Calvier L, Iñigo C, Labat C, Zhao X, Cruickshank K, Díez J, Zannad F, Lacolley P, Rossignol P.

Hypertension. 2012 Aug;60(2):563-73. doi: 10.1161/HYPERTENSIONAHA.112.194407. Epub 2012 Jun 25.

PMID:
22733458
43.

Neutrophil gelatinase-associated lipocalin is a novel mineralocorticoid target in the cardiovascular system.

Latouche C, El Moghrabi S, Messaoudi S, Nguyen Dinh Cat A, Hernandez-Diaz I, Alvarez de la Rosa D, Perret C, López Andrés N, Rossignol P, Zannad F, Farman N, Jaisser F.

Hypertension. 2012 May;59(5):966-72. doi: 10.1161/HYPERTENSIONAHA.111.187872. Epub 2012 Apr 2.

PMID:
22469622
44.

Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial.

Lopez-Andrès N, Rossignol P, Iraqi W, Fay R, Nuée J, Ghio S, Cleland JG, Zannad F, Lacolley P.

Eur J Heart Fail. 2012 Jan;14(1):74-81. doi: 10.1093/eurjhf/hfr151. Epub 2011 Nov 16.

45.

A role for cardiotrophin-1 in myocardial remodeling induced by aldosterone.

López-Andrés N, Martin-Fernandez B, Rossignol P, Zannad F, Lahera V, Fortuno MA, Cachofeiro V, Díez J.

Am J Physiol Heart Circ Physiol. 2011 Dec;301(6):H2372-82. doi: 10.1152/ajpheart.00283.2011. Epub 2011 Sep 16.

46.

Aldosterone and the cardiovascular system: a dangerous association.

Cachofeiro V, López-Andrés N, Miana M, Martín-Fernández B, de Las Heras N, Martínez E, Lahera V, Fortuño MA.

Horm Mol Biol Clin Investig. 2010 Dec 1;4(2):539-48. doi: 10.1515/HMBCI.2010.057.

PMID:
25961230
47.

Vascular effects of cardiotrophin-1: a role in hypertension?

Lopez-Andres N, Fortuno MA, Diez J, Zannad F, Lacolley P, Rossignol P.

J Hypertens. 2010 Jun;28(6):1261-72. doi: 10.1097/HJH.0b013e328337fe42.

PMID:
20216087
48.

Aldosterone induces cardiotrophin-1 expression in HL-1 adult cardiomyocytes.

López-Andrés N, Iñigo C, Gallego I, Díez J, Fortuño MA.

Endocrinology. 2008 Oct;149(10):4970-8. doi: 10.1210/en.2008-0120. Epub 2008 Jun 19.

PMID:
18566129
49.

[A campaign for detection of beta-thalassemia minor and prevention of beta-thalassemia major in the island of Minorca. 2 years' experience].

Oliva Berini E, López Andrés N, Seguí Puntas M, Hernández Pons JL, Martí Camps F.

Med Clin (Barc). 1990 Jan 27;94(3):81-4. Spanish.

PMID:
2314143
50.

[Treatment with platelet anti-aggregants].

Martínez-Brotóns F, López Andrés N.

Med Clin (Barc). 1985 Sep 28;85(9):368-70. Spanish. No abstract available.

PMID:
4079575

Supplemental Content

Loading ...
Support Center